where detecting years of life saved is of interest. The recommended test statistic looks at integrated differences in survival estimates during the time frame of interest. In many practical situations, the test statistic presented has an independent increments covariance structure. Hence, with little additional work, we may apply these testing procedures using available methodology. In the case where an independent increments covariance structure is present, we suggest how clinical trial data might be monitored using these statistics in an information-based design. The resulting study design maintains the desired stochastic operating characteristics regardless of the shapes of the survival curves being compared. This offers an advantage over the popular log-rank-based design strategy since more restrictive assumptions relating to the behavior of the hazards are required to guarantee the planned power of the test. Recommendations for how to sequentially monitor clinical trial progress in the nonindependent increments case are also provided along with an example.
Introduction
In clinical trials, we are ethically obligated to periodically monitor the performance of the treatments under study. It is important, for instance, to detect overly toxic effects that may occur and to protect the patients in the study accordingly. Also, if the new treatment under study performs substantially better than standard treatments, interim analyses of the data detect these differences early. For instance, this is a motivation for sequential analysis in most AIDS clinical trials, where there is a strong need to identify life-enhancing treatments quickly. In one such pivotal study described by Fischl et al. (1990) , patients were randomized to high-dose (n = 262) versus low-dose AZT (n = 262) with wide reaching effects on standard of care for AIDS patients upon the study's conclusion. The higher dose of AZT, which was the standard of care prior to the 1990 publication, had been shown to be an effective treatment compared to placebo but with substantial toxicity. The results observed by Fischl et al. suggested that a lower dose of AZT was more effective and less toxic than the standard. The scientists agreed at the design phase of the study that repeated analyses would preserve the best interests of the patient population.
However, a statistical price must be paid for this monitoring process. By repeatedly looking at the data, we increase our type I error probability. Hence, when analyzing data in this way, we must make adjustments in the sequential boundaries of our test statistics to maintain our type I error. Among popular stopping methods for sequential clinical trials are those suggested by Pocock (1977) and O'Brien and Fleming (1979) . More recently, flexible error spending functions have been proposed by Lan and DeMets (1983) to maintain the type I error throughout the trial.
One important requirement for using error spending functions in repeated analyses is an understanding of the joint distribution of the repeated statistical tests. For instance, the joint distribution of sequential log-rank (LR) tests as well as a framework for analyzing these repeated tests were studied by Tsiatis (1981 Tsiatis ( , 1982 , Slud (1984) , and later Gu and Lai (1991) . Because sequential methodology has been developed and studied for the LR test, it has become the primary nonparametric test applied to survival data in repeatedly moni-tored trials. In fact, this methodology was used in the highdose versus low-dose AZT study described above. The LR test is especially useful in situations where the treatment difference can be expressed as a hazard ratio assumed constant over time. For such proportional hazards alternatives, the LR test is the optimal nonparametric test. However, it often behaves poorly when hazards are not proportional. In fact, in the nonproportional hazards setting, the LR test statistic does not have a useful interpretation with respect to any treatment difference of particular interest.
An alternative to relative risk is to express treatment differences in terms of years of life saved (YLS) between treatments. That is, regardless of the behavior of the survival hazards across time, an alternative of interest in the AZT study could be defined through the YLS on the superior treatment. Since most clinical trials have limited follow-up, we would define years of life, by necessity, up to some fixed point in time after treatment. This quantity can be estimated easily with differences between areas under estimated survival curves. This resulting YLS test statistic, 7, belongs to a larger class of statistics studied by Pepe and Fleming (1989) for the nonsequential setting.
In our remaining discussion, we have three scientific goals. We shall first set up the framework for sequential methods using the 7 statistic. An important step in establishing the sequential nature of the 7 statistic is characterizing the joint distributions of the tests and survival estimates computed at different interim analyses. This will enable us to compute stopping boundaries for preserving desired operating characteristics. Jennison and Turnbull (1985) studied sequentially computed Kaplan-Meier (KM) survival estimates. Notation required in the sequential framework and results relating to the KM estimate at two separate analysis times are presented in Section 2. Subsequently, we develop methods for adapting the 7 statistic to the sequential trials setting in Section 3. In particular, we will discuss under what circumstances the 7 statistic has a joint independent increments structure. This is important because, if this is the case, we can immediately apply standard group-sequential methods to this problem.
As a second scientific goal, we shall indicate in Section 4 through simulation the performance of the 7 statistic in an information-based monitoring design when the interim test statistics have independent increments. This informationbased monitoring technique introduced by Lan and Zucker (1993) and recently formalized by Kim, Boucher, and Tsiatis (1995) and Scharfstein, Tsiatis, and Robins (1997) follows patients until the total information (TI) required to achieve the desired power is collected. During the course of the trial, error spending functions are defined according to the proportion of information collected at each interim analysis. In defining the TI required for the 7 statistic to achieve a particular power, the alternative to be detected is defined in terms of the YLS between the two treatments without any additional assumptions regarding the shapes of the underlying survival curves.
Finally, this research instructs practitioners on use of the 7 statistics in the more general nonindependent increments setting, where information-based monitoring is difficult to implement. An example in the context of the aforementioned AIDS clinical trial comparing low-dose versus high-dose AZT is given along with further simulation results in Section 5. A discussion follows in Section 6.
Sequential Methods for the Kaplan-Meier
To understand concepts relating to sequential theory, we require an explanation of notation. We borrow notation used by Tsiatis, Boucher, and Kim (1995) . Assume that n individuals will enter the trial at times E l , . . . ,En during the accrual period. These possibly different entry times will be bounded positive random variables measuring calendar time from the start of the study, which are independently and identically distributed with distribution function G(e) = P ( E 5 e ) . 
Each individual
is the censoring survival distribution among individuals entered by calendar time t . This is the usual covariance of the KM estimate at the later interim look time conditional on those entered by time t 2 .
Sequential Methods for the 7 Statistic
The sequential notation from the last section will be employed in this section as well. Temporarily, however, let us consider the case where one analysis is conducted at the end of a study. Since in this case only one analysis is performed, we submerge the calendar time subscript, t , and focus our attention on the internal patient time subscripts and random variables.
The mean survival time, E ( T ) , is equal to J r S ( u ) d u .
Hence, if consistent survival estimates were available for u E (0, 00), the area under this survival curve would consistently estimate the mean survival time in the presence of censored survival data. However, both theoretical and practical arguments might dictate an upper limit of integration, 7, different from 00. For instance, clinical investigators might be interested in studying internal patient survival time during the first r years on study. On a more practical note, the study design may not allow for estimating S(z) beyond the study time frame so that T mjght be the last point where a consistent survival estimate S ( r ) may be defined.
In both of these cases, it would be useful to consider a truncated mean, E{min(T, r)}= Jl S(z)dz. One interpretation of this truncated mean is that the area under the survival curve from 0 to 7 is the average years of life lived during T years on study. Hence, if ng is the sample size in group g at the end of the study, n = 7x1 + 122, and Sg is the KM survival estimate in group g at the end of the study, the test statistic nonparametrically compares YLS between treatments 1 and 2 during the first r years on study. Note that, notationally, with one only analysis at time t , the censoring survival function H ( t , z) = H ( z ) . To ensure that the variance of this test statistic is bounded, we shall always require that r satisfy the
is chosen close to the minimum of the largest event times from groups 1 and 2, this test statistic belongs to a larger class of statistics studied by Pepe and Fleming (1989) .
Define H g ( z ) , g = 1,2, as the probability of remaining un-
When only one statistical analysis is performed, Pepe and Fleming (1989) showed that I-+N(O, 0 2 ) , where, under the null hypothesis of no treatment difference, o2 = X(u) du, ng is the probability of falling in group g, and X(z) and S(z) are the hazard and survival functions, respectively, -common to both groups under the null hypothesis. Define S(z) as the pooled KM estimator from groups 1 and 2. Let A'(2) = J,'S(u)du, fig be the estimate for the censoring time survival probability, s(z) be the observed number of deaths at time z, Y ( z ) be the observed number of individuals still at risk at time z, and eg = ng/n. Then the variance o_f t h e A 7 statistic ma7 be estimated by oz = ki=l ?3-, J~{S(u)Hg(u)Y(u)}-1{AT(u)}2 &(u) . This corresponds to the variance estimate recommended by Pepe and Fleming (1989) .
7r3-g x JG(S(u)H,(u)}-' { A ' ( u ) }~
Note that, under the alternative hypothesis, A = f;{S1(u)
which measures the true integrated differences between survival curves in the two groups. Suppose we want to detect a clinically important treatment difference A with power 1 -p and size a using the standardized test statistic T / S E ( I ) = L/SE(A), where SE denotes standard error. This would require {var(A)}-' = A-2(z,/2 + Z P )~, where Z+ represents the 1 -* quantile of the standard normal distribution. The right-hand side of this equation is known as the total statistical information (TI) required to achieve power 1 -p. If test statistics computed at different analysis times have an independent increments covariance structure, the left-hand side of the equation suggests a natural way to measure the degree of information in a test statistic monitored across time, i.e., the inverse of the estimated variance for A can be monitored until it matches the TI required at the last analysis time. Since the TI required to achieve power 1 -p is defined in terms of A, or the average YLS that is clinically important to detect, it is robust to the actual shapes of the survival curves.
V
Using the results of the sequentially computed KM estimator, we now derive the sequential distribution of the I statistic using previous notation. If we define the 7 test evaluated at time t, as 7 ( t 3 ) = {n*(t,)}; ~: { S l ( t , , u ) -S 2 ( t , , u ) 
where n*(t,) = nl(t,)n2(t3)/n(t,), j = 1,2, then under the null hypothesis, the asymptotic distribution of 7 ( t l ) and I ( & ) is multivariate normal with mean zero and asymptotic covariance to be derived later in this section. In particular, we investigate two scenarios involving the upper limits of integration at analysis times tl and t 2 , where either rl = 7 2 or r 1 < 7 2 . These two special cases shall drive the asymptotic behavior of the sequentially evaluated statistics. The special case where r1 = r 2 = r may occur in any scenario where a particular window of time within a study is of interest. This would occur, e.g., in a clinical trial with a long accrual period and quick event times or in a case where therapy is given over a short period of time with a treatment effect expected to be realized over some time r smaller than the duration of the study. For example, patients who have experienced a myocardial infarction may be given anticoagulants for a period of 30 days with survival benefit not expected to extend beyond an initial 6-month period of high risk for the patients in the study. After 6 months, survivors should have similar risk regardless of initial treatment. In such a case, the data may be monitored periodically after 6 months using r = 6. When primary interest lies in detecting YLS during the entire study period for an event that takes a longer time to be observed, we may increase r 2 at interim analysis time 22 to compensate for an increase in the range of data observed beyond time T I .
For a 5 r1 5 r 2 , consider the expression LJo which becomes the asymptotic covariance of T(t1) and T ( t 2 ) in the case a = 0. Under the null hypothesis, this expression becomes
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To simplify notation, define ATj (z) = 12 S(u)du,j = 1,2, which at any particular analysis time t would be estimated with A T j (t,z) = J2 S(t,u)du. Continuing from (3.1), we arrive at (3.2) This covariance converges in probability to the variance identified by Pepe and Fleming (1989) in the only one analysis case where a = 0, tl = t 2 , and TI = 5.
In the special case where a = 0 and TI = T 2 , result (3.2) reveals the asymptotic covariance of 7 ( t l ) and l ( t 2 ) to be {n*(tl)}1/2{n*(t2)}-1/2~ar{7(t2)}, so that this term relates directly to the variance of the 7 statistic at interim look time t 2 . This statistic can easily be redefined with an independent increments structure. To see this, consider the statis-
( t ) . The standardized statistics 'T(t)/[var{7(t)}] 4 and l * ( t ) / [~a r ( l * ( t ) } ]~/~ are al-
gebraically equivalent definitions. Hence, for testing purposes, we may use them interchangeably. Also note that cov{7*(tl), = n*(tl)[var{l(tl)}]-l = var{l*(tl)} fulfills the standard definition of independent increments. Most of the test statistics currently used in group sequential monitoring have an independent increment structure. Hence, with little additional effort, the 7 test statistic may be adapted for sequential trials using currently available software based on the recursive numerical integration strategy of Armitage, McPherson, and Rowe (1969) .
In the case where TI < r 2 , the covariance of T(t1) and l ( t 2 ) from (3.2) for a = 0 can be described in two pieces. The first piece uses a = 0 and TI = 7-2 so that currently available software can be used in estimation; the remaining piece is identified using (3.2) with a = 71. Hence, in this case, the covariance of 'T(t1) and T ( t 2 ) is estimated under the null hypothesis with
where the integral in C2 has 7-1 as an upper limit and the pooled estimator of survival is used in calculating ATJ (t, x) .
This second scenario results in a statistic that does not have an independent increments structure.
To calculate sequential boundaries in the nonindependent increments case, we may use simulation techniques. First, a suitable spending function is selected, such as the O'BrienFleming (OF) style of spending using the function cr,f = 2 -2 @ (~, /~/ v ' /~) , where v corresponds to some surrogate for the proportion of information collected at an interim analysis time. Then we estimate the covariance structure between the current and all previous 7 test statistics calculated during the course of the trial using the observed data. Multivariate normal random variables with the observed covariance structure are simulated to estimate appropriate cutoff points for the statistics at the different analysis times that spend the predetermined type I errors as described above. An example is given in Section 5. Alternatively, software called MULNOR written by Schervish (1984) can be used to calculate sequential boundaries of the 7 statistic that satisfy the study design.
Application of Information-Based Design
We illustrate this methodology via a simulation experiment where a new treatment is compared to a standard in a randomized clinical trial. We expect treatment benefit to extend for a period of 2 years. Clinical investigators indicate that 3 months of life saved over the 2-year period (A = .25 years) is a clinically important difference to detect with 90% power at the 5% level of significance. We assume a slow but constant accrual rate of 75 eligible patients each year so that monitoring of the trial will not begin before we have at least 2 years of follow-up on some patients. Hence, T = 2 years becomes a natural truncation point at each of the interim analyses resulting in an independent increments testing structure where standard software can be employed for calculating error spending functions. A maximum information trial as recently studied by Kim et al. (1995) and Scharfstein et al. (1997) would plan the final analysis at a time when inforniation accrued matches the TI needed at the end of the study to meet power and size requirements. Using an OF error spending function with three planned analyses, the TI required at the end of the study for 90% power and 5% size is approximately 1.05A-2(1.96 + 1.28)2, where T = 2 and 1.05 is an inflation factor typically used for this style of error spending. Note that no specific forms for the survival distributions of either therapy were used to determine A or the TI required to meet study design requirements. When the sequentially computed test statistic has an independent increments covariance structure, the information accumulated is approximated using (vyr A)-' at each analysis time so that dividing this quantity by the desired TI gives the information proportion for group sequential monitoring. At the last analysis time, we would like
To plan analysis times and obtain a rough idea for how long the study will need to accrue patients before the the necessary TI is collected, we may investigate various choices for the survival distribution of the experimental therapy. From past experience, we assume the standard treatment follows an exponential distribution with hazard one. For planning purposes, we assume the survival distribution for patients on the new treatment follows an exponential with hazard ,655, resulting in the desired A = .25 years. Using Maple software, we determine that (var A)-' N TI five years from the beginning of the study if information accrues at the anticipated rate. The stopping time for the trial will be the first analysis time where the observed YLS statistic extends beyond the sequential boundaries provided from standard sequential software or the time at which we collect our TI if no rejection occurs before this time. With our first analysis planned for year 3, we monitor the percent of information accrued at monthly intervals from year 3 until the end of the trial. 
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do not depend on these assumptions being true in the independent increments setting. However, the duration of the trial may be affected by information being collected at a different rate than anticipated in the design, a s we shall witness in simulations described later in this section.
We simulated the monitoring strategy mentioned above 500 times (1) under the null hypothesis, (2) under the hypothesized exponential alternative used for planning purposes, and (3) using a Weibu11(.737,1.5) alternative that also gives us .25 YLS so that the YLS alternative is unchanged (see Figure 1) . Note that the median survival for (2) and (3) also match exactly. In planning a sequential analysis using the LR test, currently available software queries the user for median survival in the groups being compared and makes the same Simulations verifying the properties of the 7 test statistic used in conjunction with this type of study design and the OF spending function assumed uniform(0,l) entry times for patients randomized to two treatment arms. Once entered, the exponential distribution was used to simulate survival times of the two treatment groups with common mean of 1 year under the null hypothesis and an exponential alternative conferring an average of roughly 3 months of life saved around 3 years after patient recruiting began. Analyses planned at 1, 2, and 3 years from beginning of patient recruitment used the same type I error allocations as in the above example. In order to detect 3 months of life saved using three interim analyses with 90% power, a sample size of 291 per treatment group is required. In calculating this sample size, we compared the inverted variance of A at the last analysis time for the distributions described to the TI required at the last analysis time. After 500 repetitions, we estimated a type I error of 4.6% and power of 89.8% under these conditions.
Discussion
We have indicated how the YLS statistic can be incorporated in the sequential clinical trials setting. In cases where the upper limits of integration in the sequential tests are equivalent at the interim analyses, the sequential boundaries may be calculated with widely available software since an independent increments structure is present for these statistics. In cases where the primary event of interest takes a longer time to occur, the upper limits of integration of our sequential tests may increase with each additional analysis time to account for increases in the range of interesting observable survival differences. In this case, we may use a simulation strategy to calculate sequential boundaries for our tests. In either case little additional work is required to gain the benefits associated with each test in the sequential survival setting.
The sequentially monitored 7 test statistic gives an alternative to the LR test that may be more appropriate when treatment differences are more readily described through YLS over some period of follow-up. Also Pepe and Fleming (1989) have demonstrated in their research that tests focused on differences between integrated survival curves are more powerful than the LR in many situations where proportional hazards assumptions are violated. In the presence of censoring, Murray's (1994) thesis introduces an adjusted YLS statistic that increases power when prognostic covariates are available. This modified version of the YLS statistic also reduces bias associated with informative censoring when covariates related to the censoring mechanism are available. In Murray's thesis, it has been shown that the adjusted version of the test has a similar theoretical structure to the original I test in the sequential trials framework, i.e., an independent increments structure to the adjusted test statistic is also available when the upper limits of integration T remain constant across analysis times. In her thesis, Murray has also completely specified the joint distribution of the adjusted 7 statistics across analysis times so that this test can be extended to more general scenarios. Since the adjusted test corrects power loss and bias in the presence of censoring, its use would be most advantageous during the early periods of a clinical trial when censoring is heaviest.
